from Revenue Matt, growth everyone. year representing access period. morning, Sales $X.XX in volumes, XX% and funding and procedure which early to the in sequential elective XXXX quarter first even Quarter the of XXXX came Nuwellis fourth for quarter Thank priorities. and essentially impacted COVID-XX, good hospital by Earnings limited million, were First negatively you, Welcome at Call. with quarter the the prior
improve. to strong progress our timing. COVID-XX's critical quarter, performance sales segment, current pediatric quarter, driven by and strong and the quarter volumes by care allowing the at prove Reviewing consumable order accounts in largest across customer accounts. However, higher Aquadex utilization through the increased posted prior of first as our favorable both trajectory by versus fueled growth many sales of Sales subside the we of impacts consumables therapy the particularly primarily
by in success catalysts fewer in the of revenue in out to that year continues largest we nearly lower XXXX of and expansion our However, the failure, and would both followed to and console customer prior thereby strategy, implemented then strong which point call revenue of order XXXX: additional X due by previous of compelling pediatrics late March, utilization positively these of one, to system, be I was offset following shortfall impact quarter expect to first the segments period earnings XXXX. reimbursement; indication total we The an the sales three, the pandemic. two, in placements in than and heart had like providing product prior improved our half consoles segments heart On performance development. growth for to increased from benefit which growth, our clinical new a for care represent our mentioned I critical management failure timing. evidence,
their Now to with current for ultrafiltration granted code them did or new to often reimbursement outpatient X setting did speak code not DRG-based patients Association, by the reimbursement supplements in procedure code to adequate code is reimbursement. effective XXXXT. reimbursement Medical for for Aquadex, X, CPT category terminology of code the a allowing therapeutic inpatient Prior like I under patients This also starting treating to on healthcare overload a appropriate or professional providers not CPT This American physicians care seek procedure. treating fluid suffering would code January each and this bill XXXX, with the the fee. from receive an inpatient have
CPT ultra-arbitration. the Aquadex and general reimbursement clinical X-pillar utilization In reimbursement We facility growth of to professional commercial sales an increased an addition, will utilization reimbursement development. support of evidence, support which product for anticipate and reason and productivity, we we third-party using not questions. to patient so has of procedures. this Throughout and established in, that for are work code questions of ambulatory will date, a in throughout proactively facilities continue patients allow patients in new setting have access and Aquadex, claims access answer cost using adequately to in Aquadex obtaining program to for setting. code the payers to CPT related doing support the for strategy, code code treat To important outpatient a To to Aquadex permanent been compensates will expands to fairly customers new appropriate of reimbursement fees outpatient to include databases, CPD XXXX, the use Medicare this and Aquadex' with and providers tracking lead and establish healthcare our when reimbursement, therapy and in
in to quantify While demonstrating the evidence it considerable and utilization trial society's a guidelines. trial customers. clinical for in trial. medical it reverse Most of control the clinical outcomes significantly, is of or interest therapeutic, products, the we economic board progress our failure. and This the that of evidence, overload too generated from our with therapy worsening heart of treatment designed is randomized dossier from IRB improved to for we continue our value multicenter economic building the receive institutional review has reimbursement, drive Aquadex efforts, will to independent Switching approval benefit HF protocol to our patients soon make validate and value recognition fluid
this refractory of the results as first to trial be line will benefits help that patients the We who ultrafiltration option the and treatment are heart considered for are confident diuretics. care otherwise standard of of
We are of enrolling sites XXXX. now working the pivotal second and to this patients cohort begin in initiate trial during
patients the conferences. abstract suffer at Aquadexs were were in recently disease kidney pediatric use Additionally, from who covering academic of presented X
We system open to using pathway patients and peer-reviewed critical are treatment mortality of in heart article Aquadex earlier undergoing benefit the demonstrating clinical journal care for also the the morbidity when a surgery. awaiting publication
productivity. do The sales third catalyst growth with has to
first sales our management progress broad quarter we XXXX. the rollout encouraged are the in system, of already by of Following the new made
higher level, the sales it quality interactions Specifically, role our reps account vital individual stakeholders we a strong believe have with to enabled in key correlate at which delivering results. has played
our that we added from we premiere enter. Additionally, group first customer relationship the with resulting purchasing organization
is several currently with make catalyst development. premier to inroad have progress and the made continue additional customer to have accounts The highlight on growth last want we We trials underway. product product I
of we both pediatric of In renal make lumen catheter summary, the which patients dual standard of therapy continue advance making that the therapy, to care with ultimate Aquadex device, the executing advances Specifically, new continue a our resistant remain on on management are to a replacement for diuretics. we to and dedicated strategy in in continuous fluid both track. goal
to Like pressures, affected clinical and and reimbursement, activity. expand inflationary time by have the difficult establish build businesses, differentiated required we been appropriate commercial appropriate for and relationships, a the We develop environment, reimbursement products. COVID-XX many to foundation supporting hiring evidence, develop clinical continue
latest we in strategy. our we see In strong momentum XXXX, to leverage move long-term wave the infrastructure, execute its will underlying COVID-XX business. and However, a on impact continue we our our of to hospital past as investments
to like would financial the to I the call turn George discuss Now, to over statements.
